The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Biotechnology-Medicine > Biogen, Inc.

Biogen, Inc.
Nasdaq: BGEN
Change
symbol:
     
 NEWS FROM THE WIRES
VW Mexico unit's striking workers to lower wage demand
Aug 22 2001 10:47 AM PDT

Biogen, Serono both claim victory in MS court spat
Aug 19 2001 03:14 AM PDT

Biogen says Geneva court upholds injunction vs Serono
Aug 18 2001 06:47 AM PDT

Funds: Fund investors eye biotech
Aug 16 2001 09:33 AM PDT

Funds: Fund investors eye biotech
Aug 16 2001 09:33 AM PDT

More WIRE STORIES about this company

 NEWS FROM THE STANDARD
Quiet, Please, Meeting About to Start
Jun 25 2001 10:07 AM PDT

Dow Takes the High Road, and the Nasdaq? Well...
Apr 11 2000 03:37 PM PDT

 PROFILE
AVONEX calling? No peddler of cosmetics, Biogen develops biopharmaceuticals to treat a variety of ailments, primarily autoimmune conditions. Its flagship drug is AVONEX, a treatment for relapsing multiple sclerosis (MS) that accounts for about 80% of the firm's sales. Biogen licenses the drug to Schering-Plough, with which it is fighting over royalties. Facing a decline in revenues, the company is developing AMEVIVE, a potential treatment for psoriasis. Other drug candidates include a drug for MS and Crohn's disease. Biogen also makes money by licensing to other companies drugs it has developed; such products include alpha interferon and a hepatitis B vaccine, licensed to Merck, Abbott Laboratories, and others.

 COMPETITION
Schering AG (SHR)
Serono S.A. (SRA)
Teva Pharmaceutical Industries Limited (TEVA)

 STOCK ANALYSIS
 View by:
 Day 
 Day 
 Month 
 Month 
 Year 
 Year 
FURTHER ANALYSIS
• Advanced Charting
• Deals

 FINANCIAL OVERVIEW
Fiscal Year-End: December
2000 Sales (mil.): 926.50
1-Yr. Sales Growth: 16.6%
Employees: 1,475
Revenue per employee: $628,135.59

 KEY PEOPLE
• James C. Mullen
    CEO
• Peter N. Kellogg
    CFO

 CONTACT INFO
14 Cambridge Center
Cambridge, MA 02142
US
Phone: 617-679-2000
Fax: 617-679-2617
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001